Compliance · State rules

Office-use compounding in Nebraska

Permitted by Nebraska statute as a co-equal purpose of compounding; no federal condition attached

USPeptideRx EditorialLast reviewed: August 30, 2026

Nebraska permits office use as a matter of Nebraska statute, and it does so in an unusual shape: office use is one of three enumerated purposes for which a person authorised to compound may compound at all — alongside a practitioner’s medical order, and research or teaching — rather than an exception carved out of a prohibition. That wording has been in force since 2015 and is unchanged. There is no sterility split anywhere in it. The only ceiling is fiscal, it lives in a different Act, and it binds whichever party to the transaction is relevant. As everywhere, a state permission settles nothing federal.

The governing rule

Nebraska’s office-use position is set by Neb. Rev. Stat. § 38-2867.01(1)(c); ceiling at §§ 71-7444(2)(d) and 71-7454(1). The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

Neb. Rev. Stat. § 38-2867.01(1) — office use as a co-equal purpose

shall compound (a) as the result of a practitioner’s medical order … (b) for the purpose of, or as an incident to, research, teaching, or chemical analysis … or (c) for office use only and not for resale.

Neb. Rev. Stat. § 71-7454(1) — the ceiling, and note whose revenue it measures

the gross dollar value of which shall not exceed five percent of the total prescription drug sales revenue of the transferor or transferee holder of a pharmacy license or practitioner … during the immediately preceding calendar year

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

A purpose, not an exception — and the difference is not cosmeticHigh confidence: Most states that allow anything here write a prohibition and then carve out a case. Nebraska lists office use as one of the purposes for which compounding may lawfully happen. There is nothing to fall outside, and no gate to satisfy, on the face of the compounding statute itself.
What the permission does not reachHigh confidence: It is a grant of Nebraska law. The subsection carries no federal-compliance condition and no reference to the federal compounding statute, so it is genuinely effective as Nebraska law and leaves 21 U.S.C. § 353a untouched. The only external standard the statute incorporates is the USP compounding chapters, frozen as of 1 January 2023 — a private standard adopted statically, which is not federal law and should never be described as a federal hook.
No sterility split exists at allHigh confidence: The word "sterile" returns no hits across the entire relevant statutory corpus, against a working control in the same search. The only sterility handle anywhere is the USP chapters, and they are applied identically to all three compounding purposes.
The ceiling is fiscal, sits in another Act, and binds either partyHigh confidence: The compounding permission carries no cap. The limit lives in the Wholesale Drug Distributor Licensing Act: the gross dollar value of the transfers may not exceed five per cent of the total prescription drug sales revenue of the transferor OR transferee, measured over the immediately preceding calendar year. Cross it and the supplying pharmacy needs a wholesale drug distributor licence at $550 a year.Nebraska is not alone in measuring against either side — Tennessee and West Virginia write the same either-party test — but the consequence is worth spelling out wherever it appears. Measuring whichever party is relevant means a small clinic buying from a large pharmacy and a large clinic buying from a small one are not the same transaction for this purpose. It is a dollar test, not a unit test.
No label legend — and the paperwork vocabulary is a closed listHigh confidence: The compounding statute prescribes no legend. Worth knowing separately: Nebraska’s vocabulary for non-patient-specific labelling is a closed two-item list at § 38-2840 — "for emergency use" and "for use in immunizations" — and office use is not on it. That is a labelling vocabulary rather than a limit on the permission, but a reader looking for an office-use legend in Nebraska will not find one.
Last change, and a stale cross-reference to be aware ofMedium confidence: The office-use clause has been in force since 2015 and its source line shows amendment in 2023 without the clause changing. Separately, Nebraska’s regulations cite the Pharmacy Practice Act by a section range whose ceiling later legislation has moved, so the rules’ own statutory range citation is stale — a citation-hygiene point rather than a substantive one.

Nebraska at a glance

Nebraska office-use compounding summary, reviewed 2026-08-30
Human office use	Permitted by statute as a co-equal purpose
Sterile preparations	No split — the word does not appear in the statute
Quantity cap	Fiscal, in another Act: 5% of either party’s revenue
Mandatory label legend	None in the compounding statute
Board reporting	None for office use
Last change	Clause in force since 2015, unchanged
Governing rule	Neb. Rev. Stat. § 38-2867.01(1)(c); ceiling at §§ 71-7444(2)(d) and 71-7454(1)

Receiving 503B office stock in Nebraska

Nebraska is the hardest receiving side in this file to state honestly, because the answer is neither a licence nor an exemption: no outsourcing-facility credential exists in Nebraska law at all, and the department’s published answer is to telephone and ask. That is materially different from "no licence required", and it is the point most likely to be reported wrongly in the permissive direction.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Nebraska asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence: Unresolved, and unresolved by design rather than by omission on our part. Nebraska has no outsourcing-facility credential of any kind; a facility falls between the manufacturer provision at § 71-7438 and the manufacturer exemption from licensing at § 71-7447(1). The department’s own page tells an enquirer to contact its office to determine whether a wholesale drug distributor licence is required. That licence runs $550 initial and $550 on renewal, expires 1 July, and carries a separate $3,000 inspection fee plus travel.Never tell a facility that Nebraska requires no licence. The honest statement is that Nebraska has written no category and decides case by case, and that the difference between the two answers is roughly $3,550 in the first year.
Does your practice need a permit?Medium confidence: Nothing is required and nothing is available. Two trapdoors sit alongside that: a wholesale distributor licence issues only for the premises and persons named in the application and is not transferable, and a change of ownership or of premises terminates a pharmacy licence outright.
Administer vs dispenseMedium confidence: The statutory purpose is "office use only and not for resale", which speaks to what the stock is for rather than to a dispensing credential. Nebraska’s constraint on the arrangement is the fiscal ceiling in the wholesale Act rather than an administer versus dispense line.
Scheduled (controlled) stockMedium confidence: The compounding permission draws no distinction by schedule, and the limiting instrument for this state is the fiscal ceiling rather than a drug-class gate. As elsewhere in this vertical, most compounded office-use preparations are legend drugs rather than scheduled substances.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Whatever Nebraska law allows, federal law applies on top of it and is not satisfied by state permission. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Nebraska compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

Whether the department in practice requires a wholesale drug distributor licence of an outsourcing facility is unresolved, and the published answer is a telephone number. That is the difference between no licence and roughly $3,550 in the first year, and no Nebraska text settles it.
Nebraska’s own rules cite the Pharmacy Practice Act by a section range whose ceiling has since moved. The stale citation does not change the operative text quoted here, but it means a range-based lookup can miss the current sections.
We searched no case law, attorney-general opinions, board newsletters or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.